← All indications
Carcinoma, Islet Cell
A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.
Subtype terms (4)
More specific conditions that are subtypes of Carcinoma, Islet Cell in the MeSH hierarchy.
- Gastrinoma
18 drugs (14 approved, 4 experimental)
- Glucagonoma
14 drugs (11 approved, 3 experimental)
- Somatostatinoma
16 drugs (12 approved, 4 experimental)
- Vipoma
10 drugs (8 approved, 2 experimental)
Drugs by status
Phase 3 trials (1)
Phase 2 trials (22)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (25)
- Advanced Accelerator Applications
- Ipsen
- Novartis
- GlaxoSmithKline
- National Cancer Institute (NCI)
- National Cancer Institute, France
- Academic and Community Cancer Research United
- Burzynski Research Institute
- Eastern Cooperative Oncology Group
- ECOG-ACRIN Cancer Research Group
- Emory University
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Northwestern University
- Ohio State University
- Southwest Oncology Group
- Stanford University
- University of South Florida
- University of Southern California
- University of Toronto
- Mayo Clinic
- Institut Gustave Roussy
- University of Texas at Houston
- State University of New York, Buffalo
- University of Wisconsin
- National Comprehensive Cancer Network
Organization Involved with Phase 1 Indications (1)